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ABSTRACT 
Objectives: To evaluate the frequency and severity of occurrence of vincristine-associated 
neurotoxicity. 
Design: A retrospective case series study 
Setting: Burlingham Oncology Clinic, Nairobi. 
Subjects: Thirty-eight patients treated for various neoplasms with vincristine containing 
chemotherapeutic regimens. 
Main outcome measures: The frequency and degree of neurotoxicity when vincristine was 
given at the standard dose of 1.4 mg/m2• 
Results: Five patients (13.2%) developed peripheral neuropathy, one having had it even 
before vincristine was started. Therefore only four (10.5%) had it attributed to vincristine. 
Four of the patients who developed neuropathy (80%) were HIV -positive. Neuropathy grade 
2 (severe) occurred in only two patients leading to discontinuation of the drug. All the 
neurotoxicity resolved after discontinuation of vincristine. 
Conclusion: Vincristine induced neuropathy occurred but was rarely severe at a dose of 1.4 
mg/m2• It appeared to be more frequent in HIV infected individuals, but controlled studies 
with bigger sample sizes are required to determine whether this may warrant routine 
capping of the dose at a maximum of 2 mg. 
INTRODUCTION 
Vincristine is one of the oldest cytotoxic agents in 
clinical use. It has a broad spectrum of anticancer activity, 
with a recommended dose of 1.4 mg/m2 administered 
intravenously. Administrations are repeated twice weekly 
or three weekly depending on the particular regimen 
employed. Peripheral neurotoxicity is the most frequent 
and dose-limiting toxicity of vincristine( 1 ,2). When used 
in combination with mustine hydrochloride, prednisone 
and procarbazine (MOPP) protocol used in the treatment 
of Hodgkin's lymphoma in its original description(3-5), 
high remission rates and long-term relapse-free survivals 
were realised. How{;ver, when the dose is capped at the 
upper limit of 2 mg as recommended by Moore et al at 
Stanford (6), relapse-free survival is attenuated as 
experienced by Bakemeier and colleagues of ECOG(7). 
Vincristine is one of the cheapest of cytotoxic drugs, 
costing about 18 US Dollars per adult dose in Kenya on 
average. Its optimum use is therefore a matter of great 
oncologic importance, especially in economically 
disadvantaged settings. We routinely administer vincristine 
at full doses calculated at 1.4 mg/m2 to maintain the right 
dose-intensity, except in purely palliative treatments. 
MATERIALS AND METHODS 
A retrospr;~ct:v analysis of data on patients treated with 
vincristine cont<Humg regimens in our clinic between December 
1992 and May 1999 was carried out. Details of age at 
commencement of treatment, sex. histology, evidence of human 
immunodeficiency virus (HIV) infection, treatment 
employed, evidence of neurotoxicity, type of neurotoxicity, 
course of treatment at which neurotoxicity was first experienced. 
grade of neurotoxicity, treatment adjustment following 
neurotoxicity and neurotoxicity response to treatment 
discontinuation. From this information, cumulative dose of 
vincristine at which neurotoxicity was first recorded was derived. 
Peripheral neurotoxicity was graded according to World Health 
Organization (WHO) toxicity criteria (Grade 0 none observed, 
grade 1 paraesthesias and/or decreased tendon reflexes, grade 
2- severe paraesthesias and/or mild weakness, grade 3- intolerable 
paraesthcsias and/or marked motor Joss, grade 4 ·- paralysis). 
Fisher's exact test and the Z test were used to compare 
neurotoxicity between HIV positive and negative cases. 
RESULTS 
Records were evaluated for a total of 38 patients; 25 
males and 13 females. The age range was 16-72 years, 
with a median age of 38 years. Sixteen patients tested 
positive for HIVinfection while22 were negative. Twenty-
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two patients had histologic diagnosis of ma1ignant 
lymphomas, 12 had epidemic Kaposi's sarcoma, two soft 
tissue sarcomas, one multiple myeloma and one an 
anaplastic carcinoma. The median dose of vincristine per 
treatment was 2 mg and the mean dose per treatment was 
2.2 mg. The dose range per treatment was 2.0 -2.8 mg. 
Five patients (13.2%) had documented peripheral 
neuropathy and their details are included in Table 1. Their 
ages ranged between 16 and 45 years and the median age 
was 30 years. Of tht.se five patients one had neuropathy 
even before vincristine was started. She had been on 
zidovudine, didanosine and saquinavir. Only four ( 1 0.5%) 
had neuropathy attributable to vincristine. Two patients 
had neuropathy severe enough to have vincristine 
discontinued. A third patient had moderate neuropathy but 
demanded the discontinuation of vincristine after having 
been informed that it was most probably responsible for 
the symptoms. All cases of neurotoxicity resolved after 
discontinuation of vincristine even the case in whom it had 
been recorded before its initiation. 
limiting toxicity, occurs more frequently in patients who 
are older than 40 years and is related to cumulative dose. 
About 13.2% of our patients developed peripheral 
neurotoxicity though only 10.5% was attributed to 
vincristine. Because of the small sample size, no attempt 
was made to correlate occurrence of neuropathy with age. 
Eighty per-cent of our patients who developed neuropathy 
had mv infection, a condition known to predispose to 
peripheral neurotoxicity(8). Various agents utilised in 
antiretroviral therapy are also known to be neurotoxic. 
Indeed one of the five patients who had neuropathy even 
before the administration of vincristine, was infected with 
HIV and was on antiretroviral therapy. This patient was 
treated for diffuse large B cell lymphoma. Lymphomas are 
also known to predispose to neuropathy associated with 
administration of vincristine. Severe forms of neuropathy 
such as convulsions and altered mental status that are also 
known to occasionally complicate vincristine 
administration were not observed(9). 
Table 1 
Perq;hera/ueuropatlty in relation w the various protocols 
Protocol No. of 
patients 
No. with Vincristine course Grade of Vincristine For neuropathy For neuropathy 
Vincristine dose neuropathy at which neuropathy neuropathy 
occurred 
stopped? cases. intercurrent 
COP 16 4 
M-CHOP 1 2 
ABV 5 3 
BV 5 () 
MACOP-B 6 I* Severe at 2 
VAC 2 () 
BE-BVE 1 l** >20 
Others 2 () 
*Developed neuropathy even before vinc<istine was started 
**First had vincristine as a single agent many times. 
Moderate Yes Yes 2.6mg 
Mild No No 2.0mg 
Severe Yes Yes 2.0mg 
Severe Yes Yes 2mg 
Mild No Yes 2mg 
CHOP Cyclophosphamide, doxorubicin. vincristine, prednisone; M-CHOP- Methotrexate+ CHOP; ABV - Doxorubicin, bleomycin, vincristine 
BV Bleomycin. vincristine; MACOP-B - Methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone. bleomycin; V AC vincristine. 
doxorubicin, cyclophosphamide; BYE- Bleomycin. vincristine, etoposide 
Four of the patients who had neuropathy (80%) had 
tested positive for HIV infection. Only one out of22 HIV-
negative patients (4.5%) developed neuropathy, but these 
differences were not statistically signi flcant (Z= I. 84 L 
P>0.05). Twenty-five per cent of HIV -positive patients 
developed neuropathy compared with only 4.5% of HIV 
negative patients. The difference was however not 
statistically significant (P=0.09). The dose range per 
treatment was 2.2 mg. The cumulative dose at the time of 
vincristine associated peripheral neurotoxicity ranged 
between 4 to >40 mg. 
DISCUSSION 
Vincristine is virtually devoid of myelotoxicity, 
making it quite appropriate in combination chemotherapy. 
Peripheral neurotoxicity which is its most frequent dose 
Routine capping of vincristine dose at a maximum of 
2 mg as recommended by the Stanford group because of 
fear of neurotoxicity results in a dose only suitable for 
persons smaller than 1.43 m2 and this has been shown to 
have deleterious effects on outcome(6, I 0). A re-evaluation 
of full doses of vincristine regardless of body size was 
done in another study and confirmed the original NCI 
conclusion that use of full doses is feasible( 11 ). Caution 
needs to be exercised when the drug is used in intensive 
weekly schedules such as previously adopted in 
combination with cyclophosphamide and prednisone 
( CVP)( 12) which appeared to be more frequent I y associated 
with neurotoxicity (personal observations). None of our 
patients was treated with the weekly CVP combination. 
There are also antecedent neurologic disorders such as 
Charcot-Marie-Tooth disease, hereditary and sensory 
neuropathy type 1, and childhood poliomyelitis in which 
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the use of vincristine should be discouraged(13, 14 ). None 
of our patients had any of these. 
Vincristine-associated neurotoxicity occurs fairly 
frequently but appears to be rarely severe. The neuropathy 
tends to be more common in individuals infected with 
HIV. Whether this warrants routine capping of the dose of 
vincristine to a maximum of2mg needs to be addressed in 
a prospective study with a large sample size. 
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